ArticleClinical oral investigations2025
Progesterone-induced activation of progesterone receptor alleviates alveolar bone resorption and inflammatory response in periodontitis.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveProgesterone (PG) and its target, progesterone receptor (PGR), are important regulators in inflammatory diseases. This study aimed to investigate the specific role of PG in periodontitis and to elucidate the underlying mechanisms involving PGR.
methodsWomen with periodontitis, including 250 with PG deficiency, 250 with PG supplementation, and 245 controls (normal PG) were enrolled. The distance between the cemento-enamel junction to the alveolar bone crest (CEJ-ABC) and bone mineral density (BMD) were measured by cone beam computed tomography, and the levels of IL-6 and TNF-α in gingival crevicular fluid were measured by ELISA. In vitro, primary human periodontal mesenchymal stem cells (hPDLSCs) were isolated and treated with LPS in combination with PG and/or RU486 (a PGR antagonist). Osteogenic differentiation was assessed by immunofluorescence of Runx2, OCN, and ALP, and by Alizarin red staining. The inflammatory response was assessed by ELISA of IL-6 and TNF-α. Western blot was performed to evaluate the changes in the ERK/JNK/p38-MAPK signalling pathway.
resultsSignificantly higher CEJ-ABC and lower BMD were found in some teeth in the PG deficiency group than in the control and PG supplementation groups. The GCF levels of IL-6 and TNF-α were also significantly higher in the PG deficiency group. At the cellular level, PGR was up-regulated by PG in LPS-treated hPDLSCs. PG inhibits the effects of LPS on inducing inflammatory response (IL-6 and TNF-α) and inhibiting osteogenic differentiation (Runx2, OCN, ALP, and mineralised nodules) in hPDLSCs, but RU864 reversed the above effects of PG. Additionally, PG-induced activation of PGR inhibited the ERK/JNK/p38-MAPK signalling pathway in LPS-treated hPDLSCs.
conclusionsIn women with periodontitis, the alveolar bone resorption and inflammation were more pronounced with PG deficiency. In vitro, PG-induced activation of PGR signalling inhibited inflammation and promoted osteogenesis in hPDLSCs. PG supplementation may be a potential strategy to alleviate periodontitis.
Indexed as
Identifiers
40931304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.